Literature DB >> 31589133

Whole blood transcriptome analysis in bipolar disorder reveals strong lithium effect.

Catharine E Krebs1,2, Anil P S Ori1, Annabel Vreeker1,3, Timothy Wu1, Rita M Cantor1,2, Marco P M Boks4, Rene S Kahn5, Loes M Olde Loohuis1, Roel A Ophoff1,2,6.   

Abstract

BACKGROUND: Bipolar disorder (BD) is a highly heritable mood disorder with complex genetic architecture and poorly understood etiology. Previous transcriptomic BD studies have had inconsistent findings due to issues such as small sample sizes and difficulty in adequately accounting for confounders like medication use.
METHODS: We performed a differential expression analysis in a well-characterized BD case-control sample (Nsubjects = 480) by RNA sequencing of whole blood. We further performed co-expression network analysis, functional enrichment, and cell type decomposition, and integrated differentially expressed genes with genetic risk.
RESULTS: While we observed widespread differential gene expression patterns between affected and unaffected individuals, these effects were largely linked to lithium treatment at the time of blood draw (FDR < 0.05, Ngenes = 976) rather than BD diagnosis itself (FDR < 0.05, Ngenes = 6). These lithium-associated genes were enriched for cell signaling and immune response functional annotations, among others, and were associated with neutrophil cell-type proportions, which were elevated in lithium users. Neither genes with altered expression in cases nor in lithium users were enriched for BD, schizophrenia, and depression genetic risk based on information from genome-wide association studies, nor was gene expression associated with polygenic risk scores for BD.
CONCLUSIONS: These findings suggest that BD is associated with minimal changes in whole blood gene expression independent of medication use but emphasize the importance of accounting for medication use and cell type heterogeneity in psychiatric transcriptomic studies. The results of this study add to mounting evidence of lithium's cell signaling and immune-related mechanisms.

Entities:  

Keywords:  Bipolar disorder; genome-wide disease risk; lithium; neutrophils; transcriptome; whole blood

Year:  2019        PMID: 31589133     DOI: 10.1017/S0033291719002745

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  4 in total

1.  Transcriptomics and sequencing analysis of gene expression profiling for major depressive disorder.

Authors:  Pragya Verma; Madhvi Shakya
Journal:  Indian J Psychiatry       Date:  2021-12-03       Impact factor: 1.759

2.  Powerful eQTL mapping through low-coverage RNA sequencing.

Authors:  Tommer Schwarz; Toni Boltz; Kangcheng Hou; Merel Bot; Chenda Duan; Loes Olde Loohuis; Marco P Boks; René S Kahn; Roel A Ophoff; Bogdan Pasaniuc
Journal:  HGG Adv       Date:  2022-04-02

3.  Co-Expression Networks Unveiled Long Non-Coding RNAs as Molecular Targets of Drugs Used to Treat Bipolar Disorder.

Authors:  Trang Tt Truong; Chiara C Bortolasci; Briana Spolding; Bruna Panizzutti; Zoe Sj Liu; Srisaiyini Kidnapillai; Mark Richardson; Laura Gray; Craig M Smith; Olivia M Dean; Jee Hyun Kim; Michael Berk; Ken Walder
Journal:  Front Pharmacol       Date:  2022-04-08       Impact factor: 5.988

4.  A Comprehensive Evaluation of Cross-Omics Blood-Based Biomarkers for Neuropsychiatric Disorders.

Authors:  Weichen Song; Weidi Wang; Zhe Liu; Wenxiang Cai; Shunying Yu; Min Zhao; Guan Ning Lin
Journal:  J Pers Med       Date:  2021-11-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.